Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Lymphoma
FDA Approves Columvi for Select Patients With Relapsed or Refractory Large B-Cell Lymphomas
FDA Approvals, News & Updates
,
Lymphoma
,
Hematologic Malignancies
August 2023, Vol 14, No 4
On
June 15, 2023
, the FDA accelerated the approval of glofitamab-gxbm (Columvi; Genentech), a bispecific CD20-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥2 lines of systemic therapy.
Read Article
Epkinly FDA Approved for Treatment of Advanced Diffuse Large B-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
,
Hematologic Malignancies
August 2023, Vol 14, No 4
On
May 19, 2023
, the FDA accelerated the approval of epcoritamab-bysp (Epkinly; Genmab US), a bispecific CD20-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma after ≥2 lines of systemic therapy.
Read Article
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
Wayne Kuznar
NCCN
,
Leukemia
,
Lymphoma
,
NCCN 2023 Conference Highlights
,
Hematologic Malignancies
June 2023, Vol 14, No 3 - Online Only
In a session during the 2023 National Comprehensive Cancer Network (NCCN) Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and identified key factors for selecting frontline and subsequent therapies, including
IGHV
gene status, 17p deletion/
TP53
mutation status, age, patient comorbidities, and resistance mutations.
Read Article
Brukinsa Now FDA Approved for Patients with CLL or SLL
FDA Approvals, News & Updates
,
Leukemia
,
Lymphoma
February 2023, Vol 14, No 1
On
January 19, 2023
, the FDA approved zanubrutinib (Brukinsa; BeiGene USA), a Bruton tyrosine kinase (BTK) inhibitor, for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The FDA granted zanubrutinib an orphan drug designation for this indication.
Read Article
Zanubrutinib Superior to Ibrutinib in Patients with Relapsed or Refractory CLL/SLL
By
Phoebe Starr
ASH Highlights
,
Leukemia
,
Lymphoma
February 2023, Vol 14, No 1
A head-to-head phase 3 clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) has found that zanubrutinib (Brukinsa), a next-generation Bruton tyrosine kinase (BTK) inhibitor, is more effective at preventing disease progression and better tolerated than ibrutinib (Imbruvica), a first-generation BTK inhibitor that has been the current standard of care for this population of patients.
Read Article
Jaypirca Receives FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
February 2023, Vol 14, No 1
On
January 27, 2023
, the FDA accelerated the approval of pirtobrutinib (Jaypirca; Eli Lilly) for the treatment of patients with relapsed or refractory mantle-cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.
Read Article
FDA Grants Lunsumio Accelerated Approval for Relapsed or Refractory Follicular Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
February 2023, Vol 14, No 1
On
December 22, 2022
, the FDA accelerated the approval of mosunetuzumab-axgb (Lunsumio; Genentech), a bispecific CD20-directed CD3 T-cell engager, for adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. The FDA granted this indication breakthrough therapy and orphan drug designations.
Read Article
Adcetris plus Chemotherapy Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
December 2022, Vol 13, No 6
On
November 10, 2022
, the FDA approved brentuximab vedotin (Adcetris; Seagen) in combination with a chemotherapy regimen of doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVEPC) for treatment-naïve pediatric patients aged ≥2 years with high-risk classical Hodgkin lymphoma. This is the first indication for brentuximab vedotin for pediatric patients. Brentuximab vedotin has an orphan drug designation for Hodgkin lymphoma.
Read Article
Rylaze FDA Approved as Part of a Treatment Regimen for Leukemia or Lymphoma
FDA Approvals, News & Updates
,
Leukemia
,
Lymphoma
August 2021, Vol 12, No 4
On
June 30, 2021
, the FDA accelerated the approval of asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze; Jazz Pharmaceuticals), an asparagine-specific enzyme, as a component of a multidrug chemotherapy regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients aged ≥1 months with hypersensitivity to
Escherichia coli
–derived asparaginase. The FDA granted asparaginase erwinia a fast-track review and an orphan drug designation for this indication.
Read Article
Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
June 2021, Vol 12, No 3
On
April 23, 2021
, the FDA accelerated the approval of loncastuximab tesirine-lpyl (Zynlonta; ADC Therapeutics SA), an intravenous, CD19-directed antibody and alkylating agent conjugate, for the treatment of relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma, in adults who have received ≥2 lines of systemic therapy.
Read Article
Page 1 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma